See more : Pennsylvania Real Estate Investment Trust (PEI-PC) Income Statement Analysis – Financial Results
Complete financial analysis of CV Sciences, Inc. (CVSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CV Sciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Xiwang Foodstuffs Co.,Ltd. (000639.SZ) Income Statement Analysis – Financial Results
- NOV Inc. (NOV.MX) Income Statement Analysis – Financial Results
- Chuzhou Duoli Automotive Technology Co., Ltd. (001311.SZ) Income Statement Analysis – Financial Results
- Compagnie de Chemins de Fer Départementaux Société Anonyme (MLCFD.PA) Income Statement Analysis – Financial Results
- Beyond Commerce, Inc. (BYOC) Income Statement Analysis – Financial Results
CV Sciences, Inc. (CVSI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cvsciences.com
About CV Sciences, Inc.
CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.00M | 16.21M | 20.05M | 24.43M | 53.70M | 48.24M | 20.68M | 11.06M | 11.53M | 10.19M | 2.15M | 0.00 | 0.00 |
| Cost of Revenue | 8.92M | 10.66M | 11.43M | 13.42M | 18.61M | 14.37M | 6.19M | 4.06M | 4.42M | 4.39M | 880.47K | 0.00 | 0.00 |
| Gross Profit | 7.09M | 5.55M | 8.62M | 11.01M | 35.09M | 33.88M | 14.49M | 7.00M | 7.11M | 5.80M | 1.27M | 0.00 | 0.00 |
| Gross Profit Ratio | 44.27% | 34.25% | 42.98% | 45.07% | 65.35% | 70.22% | 70.06% | 63.27% | 61.65% | 56.95% | 59.13% | 0.00% | 0.00% |
| Research & Development | 151.00K | 307.00K | 1.19M | 2.94M | 5.88M | 1.89M | 724.33K | 1.16M | 1.32M | 999.28K | 524.48K | 0.00 | 0.00 |
| General & Administrative | 6.55M | 3.89M | 13.93M | 19.36M | 34.39M | 21.75M | 16.25M | 13.13M | 17.75M | 13.36M | 2.37M | 0.00 | 88.09K |
| Selling & Marketing | 2.94M | 8.20M | 11.95M | 11.30M | 12.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.49M | 12.09M | 25.88M | 30.66M | 46.45M | 21.75M | 16.25M | 13.13M | 17.75M | 13.36M | 2.37M | 43.02K | 88.09K |
| Other Expenses | -5.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -12.27K | -8.55K | -73.21K | -34.82K | 0.00 | 43.02K | 0.00 |
| Operating Expenses | 3.73M | 12.40M | 27.06M | 33.60M | 52.33M | 23.63M | 16.98M | 13.91M | 19.07M | 14.36M | 2.89M | 43.02K | 88.09K |
| Cost & Expenses | 12.64M | 23.05M | 38.49M | 47.02M | 70.94M | 38.00M | 23.17M | 17.97M | 23.50M | 18.74M | 3.77M | 43.02K | 88.09K |
| Interest Income | 0.00 | 1.54M | 140.00K | 9.00K | 15.00K | 0.00 | 2.00 | 27.66K | 18.29K | 30.70K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.54M | 140.00K | 9.00K | 0.00 | 153.00K | 506.38K | 1.09M | 968.62K | 615.34K | 372.11K | 2.59K | 2.09K |
| Depreciation & Amortization | 235.00K | 1.06M | 1.50M | 1.47M | 1.53M | 519.00K | 182.00K | 1.05M | 1.01M | 933.60K | 767.25K | 43.02K | 0.00 |
| EBITDA | 3.85M | -5.66M | -14.00M | -21.72M | -15.69M | 10.77M | -4.69M | -12.00M | -10.25M | 236.99K | -1.16M | -2.59K | -88.09K |
| EBITDA Ratio | 24.03% | -36.13% | -86.26% | -88.91% | -30.77% | 22.32% | -11.21% | -52.80% | -95.49% | -75.19% | -39.46% | 0.00% | 0.00% |
| Operating Income | 3.36M | -6.85M | -18.45M | -22.59M | -17.24M | 10.25M | -4.86M | -13.07M | -11.21M | -8.55M | -1.62M | -43.02K | -88.09K |
| Operating Income Ratio | 20.99% | -42.25% | -92.01% | -92.48% | -32.11% | 21.24% | -23.50% | -118.20% | -97.23% | -83.93% | -75.08% | 0.00% | 0.00% |
| Total Other Income/Expenses | -264.00K | -1.41M | 2.81M | -9.00K | 15.00K | -153.00K | -519.00K | -1.07M | -1.02M | 7.24M | -682.86K | -2.59K | -2.09K |
| Income Before Tax | 3.10M | -8.26M | -15.64M | -22.60M | -17.23M | 10.09M | -5.38M | -14.14M | -12.23M | -1.31M | -2.30M | -45.61K | -90.18K |
| Income Before Tax Ratio | 19.35% | -50.98% | -78.02% | -92.52% | -32.08% | 20.92% | -26.01% | -127.85% | -106.10% | -12.87% | -106.78% | 0.00% | 0.00% |
| Income Tax Expense | -6.00K | -47.00K | -87.00K | -317.00K | -615.00K | 93.00K | -481.50K | 1.08M | 895.40K | 541.98K | 372.11K | -43.02K | 0.00 |
| Net Income | 3.10M | -8.21M | -15.55M | -22.28M | -16.61M | 10.00M | -4.90M | -14.14M | -12.23M | -1.31M | -2.30M | -45.61K | -90.18K |
| Net Income Ratio | 19.38% | -50.69% | -77.58% | -91.22% | -30.93% | 20.73% | -23.68% | -127.85% | -106.10% | -12.87% | -106.78% | 0.00% | 0.00% |
| EPS | 0.02 | -0.06 | -0.14 | -0.22 | -0.17 | 0.09 | -0.06 | -0.27 | -0.35 | -0.04 | -0.23 | -0.01 | -0.01 |
| EPS Diluted | 0.02 | -0.06 | -0.14 | -0.22 | -0.17 | 0.09 | -0.06 | -0.27 | -0.35 | -0.04 | -0.23 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 153.95M | 138.03M | 107.82M | 99.91M | 97.86M | 111.12M | 80.43M | 52.66M | 35.14M | 31.58M | 9.88M | 7.00M | 6.97M |
| Weighted Avg Shares Out (Dil) | 153.96M | 138.03M | 107.82M | 99.91M | 97.86M | 114.47M | 80.43M | 52.66M | 35.14M | 31.58M | 9.88M | 7.00M | 6.97M |
CV SCIENCES, INC. ACQUIRES ELEVATED SOFTGELS, A FLEXIBLE, LOW-MOQ, NUTRACEUTICAL MANUFACTURER
CV Sciences, Inc. To Announce First Quarter 2024 Results On May 14, 2024
CV Sciences, Inc. (CVSI) Q4 2023 Earnings Call Transcript
CV Sciences, Inc. Reports Fiscal Year-End 2023 Financial Results
CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet Chews
CV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2023 RESULTS ON MARCH 28, 2024
CV Sciences, Inc. Acquires Cultured Foods To Enter Plant-Based Food Market, Opening Door For European Distribution
CV Sciences, Inc. (CVSI) Q3 2023 Earnings Call Transcript
CV Sciences, Inc. Reports Third Quarter 2023 Financial Results
CV SCIENCES, INC. TO ANNOUNCE THIRD QUARTER 2023 RESULTS ON NOVEMBER 14, 2023
Source: https://incomestatements.info
Category: Stock Reports